HF 4852: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Plain-language summary

HF 4852 is a bill introduced in the Minnesota House on April 7, 2026. According to its official title, it concerns: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council. Primary sponsor: Liz Reyer (Democratic-Farmer-Labor). It lists 1 additional sponsor. Most recent recorded action (April 7, 2026): Introduction and first reading, referred to Health Finance and Policy.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written